Get startedLog in
    Picture of Viracta Therapeutics logo

    VIRX — Viracta Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Viracta Therapeutics Announces Orphan Drug Designation Granted By FDA For Its All-Oral Combination Of Nanatinostat And Valganciclovir (Nana-Val) For The Treatment Of Epstein Barr Virus-Positive Diffuse Large B-Cell Lymphoma

    Picture of Viracta Therapeutics logoViracta Therapeutics
    29/11/2021 13:24
    Nov 29 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
BY FDA FOR ITS ALL-ORAL COMBINATION OF NANATINOSTAT AND
VALGANCICLOVIR (NANA-VAL) FOR THE TREATMENT OF EPSTEIN BARR
VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
    * VIRACTA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
BY FDA FOR ITS ALL-ORAL COMBINATION OF NANATINOSTAT AND
VALGANCICLOVIR (NANA-VAL) FOR THE TREATMENT OF EPSTEIN BARR
VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

Source text for Eikon:  ID:nPnz6WBWa 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Viracta Therapeutics

    See all news